- Two platforms, two manufacturing paradigms
- How do the upstream production systems for AAV and lentiviral vectors compare?
- Downstream purification: different challenges at every step
- What cold chain and stability requirements separate the two platforms?
- Clinical application scope and the manufacturing consequence of delivery route
- What does the platform choice mean for long-term commercial manufacturing strategy?
Choosing between adeno-associated virus and lentiviral vector platforms for gene therapy involves far more than biology. The production system, downstream purification, cold chain requirement, biosafety classification, and scale-up pathway differ substantially between the two. Understanding these manufacturing differences is essential when selecting the vector platform that will carry a program from early clinical development to commercial supply.
Key takeaways |
|
|
|
|
|
This article focuses on the manufacturing platform differences between AAV and lentiviral vectors. For the gene delivery biology, tropism, and therapeutic indication context that informs the initial platform selection decision, see the related DDN coverage of viral vs. non-viral gene delivery: a critical choice for gene therapy developers. The two articles are designed as complements: biology and delivery in that article, manufacturing and process development here.
Two platforms, two manufacturing paradigms
The surface similarity between AAV and lentiviral vector manufacturing, both produced in HEK293 cells by transient transfection, obscures a deeper divergence in what the two processes are actually producing and what those products require downstream. AAV is a small, non-enveloped icosahedral capsid approximately 25 nanometers in diameter, produced by the simultaneous expression of the rep and cap genes and an adenoviral helper function from three separate plasmids. The assembled capsid either packages the therapeutic gene sequence or remains empty, and the two species are physically almost indistinguishable.
A lentiviral vector is an enveloped retroviral particle approximately 100 to 200 nanometers in diameter, produced by a three or four-plasmid system that provides the retroviral gag-pol structural proteins, the envelope glycoprotein (typically VSV-G for broad tropism in clinical applications), and the RNA transfer vector carrying the therapeutic gene. The envelope makes lentiviral particles fragile: VSV-G-pseudotyped vectors are sensitive to shear forces, detergent-like conditions, temperature excursions, and freeze-thaw cycles in ways that compromise titer and infectivity. The absence of an envelope is a key advantage of AAV for cold chain management.
The manufacturing implications of these structural differences drive every decision from bioreactor design through formulation. A comprehensive review of lentiviral vector bioprocessing confirmed that the envelope protein is a central determinant of LV bioprocessing design, affecting not only downstream stability but the processing temperature and detergent exposure limits that constrain every step from harvest clarification through formulation. A process designed around VSV-G stability cannot use the same shear forces, detergents, or temperature profiles that AAV downstream processing tolerates.
How do the upstream production systems for AAV and lentiviral vectors compare?
Both AAV and lentiviral vectors are produced by transient transfection of HEK293 cells, but the transfection systems differ in their plasmid count, the stoichiometry requirements for each plasmid, and the duration of the productive phase after transfection. A 2025 review of AAV yield and quality improvements across production methods summarized that AAV production at laboratory scale achieves 10^12 to 10^14 vector genomes per liter, with the major bottleneck being recovery from large volumes of cell lysate or production medium rather than the upstream production step itself.
AAV upstream production has scaled to suspension bioreactors from 50 liters to over 2,000 liters with adapted suspension HEK293 cells, providing the volumetric production capacity required for clinical and commercial programs. The scalability of AAV upstream production is substantially better than lentiviral vectors, partly because AAV capsids are more stable to the hydrodynamic shear forces of large-scale agitated bioreactors than enveloped lentiviral particles.
Lentiviral vector production faces a fundamental scale-up challenge from the toxicity of the VSV-G envelope protein to the producing cells. VSV-G is expressed from a constitutive promoter in many production systems, but sustained high-level VSV-G expression causes cell death within 48 to 72 hours of transfection, limiting the duration of the productive phase. Stable producer cell lines with inducible VSV-G expression are being developed as a route to more scalable and consistent lentiviral vector production. Research using stable HEK293 producer cell lines with perfusion processing for lentiviral vector production demonstrated a 1.5-fold improvement in cumulative functional yield compared to the same cell line run in batch mode, showing that advanced bioprocessing approaches can partially offset the yield limitations of transient transfection.
A key upstream difference is the harvest mode. AAV can be harvested from either the cell lysate (for non-secreted serotypes), the culture medium (for secreted serotypes such as AAV9), or both. Lentiviral vectors are exclusively secreted into the conditioned medium and harvested by clarification of the bulk culture supernatant, which is typically at a lower product concentration than AAV lysate and requires larger volume processing at downstream steps.
Downstream purification: different challenges at every step
AAV downstream purification must achieve two objectives simultaneously: remove process-related impurities including host cell proteins, DNA, and empty capsids, and do so at a scale that makes commercial manufacturing economically viable. The empty-to-full capsid separation is the primary technical challenge, because empty capsids are physically nearly identical to full capsids in size, charge, and density, and the chromatographic and density-based separation methods that can resolve them are poorly scalable to commercial volumes.
Lentiviral vector downstream processing faces a different primary challenge: maintaining infectivity throughout a purification process that must remove host cell DNA, proteins, and process-related impurities from a large volume of conditioned medium, while protecting the fragile VSV-G envelope from shear, detergent, and temperature conditions that reduce transduction efficiency. Benzonase treatment to digest host cell DNA, tangential flow filtration to concentrate the vector, and anion exchange chromatography to capture the vector are the standard unit operations, but each must be optimized to limit envelope damage and functional titer loss.
Final concentration of lentiviral vectors by ultracentrifugation, which is used in many clinical programs, is not scalable to commercial manufacturing volumes. Alternative concentration methods, including TFF with appropriate membrane cutoffs and optimized conditions, and anion exchange chromatography-based concentration, are the approaches used in commercial-scale LV processing to replace ultracentrifugation. Functional titer, measured in transduction units rather than physical particles, is the primary release criterion for lentiviral vectors, and functional titer loss during processing directly reduces the potency of the product available for cell transduction.
What cold chain and stability requirements separate the two platforms?
The cold chain requirements of the two vector platforms reflect the fundamental stability difference between a non-enveloped icosahedral capsid and an enveloped retroviral particle. AAV capsids are robust, compact protein shells that protect the encapsulated DNA from degradation across a wide temperature range. Depending on the serotype and formulation, AAV vectors can be stored at 4 degrees Celsius for months without significant loss of titer or infectivity, and lyophilized AAV formulations under development target room-temperature or refrigerator-temperature storage for distribution in settings where ultra-cold storage is not available.
Lentiviral vectors must be stored at minus 80 degrees Celsius because VSV-G-pseudotyped particles lose infectivity during freeze-thaw cycles as the envelope fusion protein is irreversibly denatured by the ice crystal formation and membrane disruption associated with freezing. Each freeze-thaw cycle reduces titer by approximately 20 to 50 percent depending on the formulation, making multiple freeze-thaw events in the supply chain a significant potency risk. Commercial lentiviral vector drug products for ex vivo use are typically formulated in cryoprotectant-containing buffers that reduce but do not eliminate freeze-thaw losses.
The cold chain difference has supply chain implications that affect the operational design of ex vivo cell therapy programs. Lentiviral vector must be shipped from the manufacturing site to the processing facility at minus 80 degrees Celsius in dry ice or liquid nitrogen containers, adding cost and logistical complexity. For decentralized processing models, where ex vivo transduction is performed at multiple sites close to patients, the cold chain requirements for lentiviral vector supply are a significant operational constraint that AAV supply chains do not face.
Clinical application scope and the manufacturing consequence of delivery route
The therapeutic applications of AAV and lentiviral vectors reflect the properties of each platform in a way that creates distinct manufacturing contexts for each. AAV is used for in vivo gene delivery, administered directly to patients by intravitreal injection (Luxturna for RPE65-associated retinal dystrophy), intrathecal injection (Zolgensma for spinal muscular atrophy at higher doses), intravenous infusion, or intramuscular injection. The vector is the drug product: it leaves the manufacturing site as a finished formulated drug and is administered to the patient.
Lentiviral vectors are used for ex vivo gene therapy: the vector leaves the manufacturing site as an intermediate that is used to modify patient cells at a cell processing facility, and the final drug product is the modified cell population. This means that lentiviral vector supply is embedded into a cell therapy manufacturing workflow with its own scheduling, quality control, and logistics requirements. The vector must be available when the patient cells arrive at the processing facility, and any supply delay affects the entire patient treatment timeline.
For the viral vector manufacturing process development context that applies specifically to AAV scale-up, including suspension HEK293 optimization, the empty capsid separation challenge, and the transition from transient transfection to stable producer systems, see the related DDN article on scaling up viral vector manufacturing for gene therapies.
What does the platform choice mean for long-term commercial manufacturing strategy?
The commercial manufacturing strategy for a gene therapy program is shaped by the vector platform decision from the earliest stages of development. AAV programs can pursue a platform manufacturing approach with shared facility infrastructure across multiple programs once the upstream HEK293 suspension culture and downstream purification processes are established, because the AAV capsid structure is similar across serotypes even when the gene payload changes. The resin, conditions, and analytical methods developed for one AAV program can be transferred to a new serotype with adaptation rather than complete re-development.
Lentiviral vector programs face a different manufacturing strategy because the integrating nature of the vector creates a genotoxicity risk that is product-specific and requires individual regulatory demonstration. The self-inactivating vector design, which deletes the U3 promoter region from the long terminal repeat after integration to prevent activation of nearby cellular genes, is the standard approach for all clinical lentiviral vectors. However, the integration site profile of each specific vector is still product-specific and must be characterized individually.
The regulatory context for demonstrating manufacturing comparability and safety for both AAV and lentiviral vector programs is addressed in the related DDN coverage of why gene and cell therapies are stalling at the FDA. The manufacturing characterization, potency assay development, and comparability demonstration gaps identified there as common causes of regulatory delay apply equally to both vector platforms, though the specific assays and comparability parameters differ between them.
Manufacturing dimension | AAV | Lentiviral vector |
Upstream production host | HEK293 suspension (preferred at scale) or adherent; triple transfection with rep/cap, helper, and transgene plasmids; baculovirus/Sf9 alternative for some serotypes | HEK293 adherent or suspension; three or four plasmids (gag-pol, VSV-G envelope, transfer vector, and sometimes Rev); VSV-G toxicity limits productive window to 48-72 hours |
Production yield | 10^12 to 10^14 vector genomes per liter at clinical development scale; highly serotype-dependent; baculovirus system can achieve higher titers for some serotypes | 10^8 to 10^9 transduction units per mL after purification; functional titer is lower than physical particle count due to non-functional particle fraction |
Cargo capacity | Approximately 4.7 kilobases; limits the size of therapeutic gene cassettes that can be packaged; dual-vector strategies used for larger genes | Approximately 8 kilobases; sufficient for most therapeutic gene cassettes including large coding sequences and regulatory elements |
Primary downstream challenge | Empty capsid separation: empty and full capsids are nearly identical in physical properties; ultracentrifugation or optimized ion exchange required | Infectivity preservation: VSV-G envelope is fragile; shear, detergent, and freeze-thaw reduce functional titer; scale-up from ultracentrifugation to TFF and AEX required for commercial volumes |
Cold chain requirement | 2 to 8 degrees Celsius stability for weeks to months possible for many serotypes; lyophilization under development for room-temperature distribution | Minus 80 degrees Celsius required; freeze-thaw causes 20-50% titer loss per cycle; cold chain from manufacturing to ex vivo processing site must be maintained throughout |
Integration profile | Predominantly episomal; does not integrate into host genome in most cell types; episomes lost during cell division, limiting use to post-mitotic tissues or requiring re-dosing (limited by immune response) | Integrating: stable genomic integration provides durable expression across cell divisions; essential for ex vivo HSC and T cell therapy; SIN design required to reduce insertional mutagenesis risk |
Delivery route and context | In vivo: vector administered directly to patient; vector is the drug product; manufacturing supplies the clinical site | Ex vivo: vector transduces patient cells outside the body; vector is a manufacturing intermediate; must be available when patient cells arrive at cell processing facility |
Commercial strategy fit | Platform manufacturing feasible across serotypes; shared infrastructure; scale-up well-characterized at 200L to 2000L bioreactor scale | Product-specific regulatory characterization required; integration site profile is product-specific; tight coupling to ex vivo cell therapy supply chain adds scheduling complexity |
This article was produced under Drug Discovery News' AI Editorial Guidelines.
